PROCEPT BioRobotics Corporation to Report Third Quarter 2026 Financial Results on November 4, 2026

2026-10-12

Investivoq

PROCEPT BioRobotics will report Q3 2026 financial results on November 4, with a conference call at 4:30 PM ET.

Investivoq AI Summary

PROCEPT BioRobotics Corporation announced it will report its financial results for the third quarter of 2026 on November 4, 2026, after market close, followed by a conference call at 4:30 p.m. Eastern Time. The company, which specializes in surgical robotics for urology, is known for its AQUABEAM and HYDROS Robotic Systems, the latter being the only AI-powered technology that administers Aquablation therapy. This therapy aims to provide effective treatment for men with lower urinary tract symptoms due to benign prostatic hyperplasia (BPH), a condition affecting around 40 million men in the U.S. PROCEPT is also involved in clinical research for prostate cancer, and has a robust portfolio of approximately 250 peer-reviewed publications supporting its technology. Investors can access the conference call via a webcast or a dial-in link, with archived recordings available for 90 days.

Potential Positives

The announcement of the upcoming financial results indicates transparency and encourages investor engagement.
The release highlights PROCEPT BioRobotics' leadership in BPH treatment, which is significant given the widespread impact of this condition on men's health.
The mention of the AQUABEAM® and HYDROS® Robotic Systems underlines the company's innovative product offerings in the surgical robotics market.
The company boasts a substantial body of clinical evidence with around 250 peer-reviewed publications, reinforcing the efficacy and safety of its Aquablation therapy.

Potential Negatives

There is no mention of financial performance expectations or guidance leading up to the earnings report, which could indicate uncertainty or lack of confidence in future results.
The press release does not address any current challenges or competition within the surgical robotics market, which could raise concerns among investors about the company's positioning.
Potential reliance on the performance of a single product, the AQUABEAM®, without clear differentiation or updates on other product lines could be seen as a risk factor for future growth.

FAQ

When will PROCEPT BioRobotics report its Q3 2026 financial results?

PROCEPT BioRobotics will report its Q3 2026 financial results on November 4, 2026, after market close.

What time is the conference call for PROCEPT BioRobotics’ financial results?

The conference call will begin at 4:30 p.m. Eastern Time on November 4, 2026.

Where can I listen to the PROCEPT BioRobotics conference call?

Listeners can access the conference call via a webcast link or through dial-in registration for analysts.

What technologies does PROCEPT BioRobotics develop?

PROCEPT BioRobotics develops surgical robotics solutions, including the AQUABEAM® and HYDROS® Robotic Systems for urology.

How does Aquablation therapy benefit patients with BPH?

Aquablation therapy provides effective, safe, and durable outcomes for men suffering from lower urinary tract symptoms, regardless of prostate size.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$PRCT Insider Trading Activity

$PRCT insiders have traded $PRCT stock on the open market 7 times in the past 6 months. Of those trades, 1 have been purchases and 6 have been sales.

Here’s a breakdown of recent trading of $PRCT stock by insiders over the last 6 months:

LARRY L WOOD (President, CEO) purchased 23,900 shares for an estimated $498,315
BARRY L TEMPLIN (EVP, Chief Technology Officer) has made 0 purchases and 2 sales selling 731 shares for an estimated $18,010.
KEVIN WATERS (EVP, CFO) has made 0 purchases and 2 sales selling 730 shares for an estimated $17,982.
ALALEH NOURI (EVP, CLO, CORP. SEC.) has made 0 purchases and 2 sales selling 582 shares for an estimated $14,339.

To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

$PRCT Revenue

$PRCT had revenues of $94.5M in Q2 2026. This is an increase of 19.34% from the same period in the prior year.

You can track PRCT financials on Investivoq's PRCT stock page.

You can access data on PRCT stock through the Investivoq API.

$PRCT Hedge Fund Activity

We have seen 138 institutional investors add shares of $PRCT stock to their portfolio, and 100 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 2,880,156 shares (+747.0%) to their portfolio in Q2 2026, for an estimated $65,033,922
MACKENZIE FINANCIAL CORP removed 1,720,738 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $38,854,264
PROSIGHT MANAGEMENT, LP removed 1,676,731 shares (-86.2%) from their portfolio in Q2 2026, for an estimated $37,860,585
POINT72 ASSET MANAGEMENT, L.P. removed 1,128,543 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $25,482,500
FEDERATED HERMES, INC. added 1,078,984 shares (+618.6%) to their portfolio in Q2 2026, for an estimated $24,363,458
SOLEUS CAPITAL MANAGEMENT, L.P. added 843,000 shares (+526.9%) to their portfolio in Q2 2026, for an estimated $19,034,940
PRICE T ROWE ASSOCIATES INC /MD/ added 726,494 shares (+119.9%) to their portfolio in Q2 2026, for an estimated $16,404,234

To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

$PRCT Price Targets

Multiple analysts have issued price targets for $PRCT recently. We have seen 4 analysts offer price targets for $PRCT in the last 6 months, with a median target of $29.5.

Here are some recent targets:

Richard Newitter from Truist Securities set a target price of $25.0 on 07/06/2026
Vijay Kumar from Evercore ISI Group set a target price of $30.0 on 06/24/2026
Mike Kratky from Leerink Partners set a target price of $29.0 on 06/11/2026
Matt O'Brien from Piper Sandler set a target price of $35.0 on 04/30/2026

Full Release

SAN JOSE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2026 after market close on Wednesday, November 4, 2026. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by following one of the below links:

Webcast link for interested listeners:
- https://edge.media-server.com/mmc/p/szcd72rr
Dial-in registration for sell-side research analysts:
- https://register-conf.media-server.com/register/BIfa3afbb003f14ef1af5711014b40f3d3

Live audio of the webcast will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com .

An archived recording will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com . Each webcast will be available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation

PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The Company manufactures the AQUABEAM ^® and HYDROS ^® Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. In addition to its leadership in BPH treatment, the Company is pursuing clinical research initiatives in prostate cancer utilizing investigational applications of its robotic and AI-enabled technologies. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Media Contact: Pooja Rao, media@procept-biorobotics.com
Investor Contact: Marissa Bych, ir@procept-biorobotics.com